Inspire Medical Systems (NYSE:INSP) Upgraded at Freedom Capital

Freedom Capital upgraded shares of Inspire Medical Systems (NYSE:INSP) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. lowered their price objective on Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. Mizuho reduced their price target on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. Zacks Research cut shares of Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 13th. Wells Fargo & Company cut their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 5th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Inspire Medical Systems in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $81.05.

Inspire Medical Systems Stock Up 3.3%

Shares of NYSE INSP opened at $46.95 on Tuesday. The firm has a 50-day simple moving average of $44.71 and a 200-day simple moving average of $62.53. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 10.46, a price-to-earnings-growth ratio of 4.60 and a beta of 0.71. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. During the same period in the previous year, the business posted $0.10 earnings per share. Inspire Medical Systems’s quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts expect that Inspire Medical Systems will post 0.93 EPS for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP purchased a new position in shares of Inspire Medical Systems during the fourth quarter worth about $203,929,000. Wasatch Advisors LP raised its stake in Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after acquiring an additional 110,288 shares during the last quarter. Morgan Stanley raised its stake in Inspire Medical Systems by 179.5% during the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after acquiring an additional 809,121 shares during the last quarter. Deerfield Management Company L.P. lifted its position in Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after acquiring an additional 907,694 shares during the period. Finally, State Street Corp lifted its position in Inspire Medical Systems by 2.3% during the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after acquiring an additional 22,843 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.